In recent years, more and more studies have shown that glycosylation is closely related to the occurrence and development of various diseases. Abnormal glycosylation may lead to protein dysfunction, which in turn affects cell-to-cell recognition, signal transduction, immune response, and other life activities, thereby causing or exacerbating a variety of diseases.
At CD BioGlyco, we rely on our rich experience and professional technical team to provide clients with high-quality Glycobiology Disease Model Development Services, including Custom In Vivo Glycobiology Disease Model Service, In Vivo Glycobiology Disease Model Screening Service, and In Vitro Glycobiology Disease Model Screening Service.
We provide comprehensive glycobiology disease model construction service to meet the needs of scientific researchers and pharmaceutical developers for glycosylation-related disease models. Our services cover but are not limited to the following disease models.
We construct reliable animal models to study the connection between glycosylation, autoimmunity, and inflammation. Aberrant glycosylation is often associated with autoimmune and inflammatory conditions, and the model is developed to accelerate the detection and development of drugs targeting these diseases.
We construct high-standard models to study the impact of glycosylation in the pathogenesis of gastrointestinal diseases. We reveal underlying mechanisms through these models.
In cardiovascular diseases, abnormal glycosylation may be involved in processes such as proliferation, migration, inflammatory response, and thrombosis of blood vessel wall cells. Our cardiovascular model construction service aims to construct cardiovascular disease models that simulate these glycosylation abnormalities to study their role in cardiovascular disease.
In kidney disease, abnormal glycosylation may affect the function of the glomerular filtration barrier, tubular reabsorption function, and renal inflammatory response. We establish kidney disease models by studying the glycosylation process and the pathophysiological changes it causes, which is crucial for studying effective treatments and related drug screening.
In fibrotic diseases, abnormal glycosylation may promote excessive proliferation and deposition of fibrotic tissue. Our fibrosis disease model construction service builds fibrosis disease models that simulate these glycosylation abnormalities to study their role in the fibrosis process.
We also provide other model construction services and customized services for glycosylation-related diseases. No matter which disease you are concerned about, we are willing to provide you with professional solutions.
Our glycobiology disease model construction services process consists of multiple stages. First, we use advanced glycomics technology to analyze the composition, structure, and functional changes of glycans in disease states. Next, methods such as chemistry, biology, and synthetic biology are used to precisely synthesize or modify these glycans to simulate disease states. Finally, these glycans are integrated into cells or animal models to create disease models that simulate the disease process.
First, we collect disease samples and use glycomic technologies such as mass spectrometry and nuclear magnetic resonance to conduct a comprehensive analysis of disease-related glycans. We identify relevant glycan structures associated with specific diseases. We do this using a range of advanced glycobiology tools and techniques, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR).
Based on the analysis results of disease glycans, we use chemical synthesis, enzymatic synthesis, and other methods to accurately synthesize or transform these glycan chains. This process requires highly precise techniques and extensive experience to ensure that the structure and function of the glycan chains are consistent with the disease state.
We integrate synthetic or modified glycans into cells or animal models to construct disease models that can simulate the disease process. To construct these models, we utilize state-of-the-art genetic engineering techniques to embed relevant glycan structures into in vitro or in vivo models. This involves altering the genes of bacteria, animal cells, or animals to produce the desired glycans. This process requires comprehensive consideration of the interaction between glycan chains and cells and tissues, as well as the complexity of the disease process.
We perform comprehensive bioassays to test whether the model correctly simulates the disease of interest. This includes studying changes in glycan structure in diseased and healthy states and the impact on cell function. Based on the experimental results, the model is optimized and improved to improve its predictive ability and application value.
Technology: Development of human stem cell-based cell culture models
Journal: Molecular & Cellular Proteomics
IF: 7.0
Published: 2016
Results: The researchers created human stem cell-based cell culture models that gradually reduced levels of N-glycosylation. The team succeeded in generating induced pluripotent stem cells (iPSCs) from the fibroblasts of a patient suffering from the genetic disorder phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), which they labeled as PMM2-iPSCs. The authors found that the PMM2-iPSC-C3 model exhibited the usual N-glycosylation pattern found in hPSC with high-mannose-type N-glycans being the dominant species.
Fig.1 Scheme for N-glycosylation in PMM2-IPSC models. (Thiesler, et al., 2016)
At CD BioGlyco, our glycobiology disease model construction service provides scientific researchers and pharmaceutical developers with powerful research tools. We have rich technical experience and a professional team to provide clients with high-quality disease models. Please feel free to contact us if you are interested in our glycobiology disease model construction service.
Reference
